Blueshift Asset Management’s Oric Pharmaceuticals ORIC Stock Holding History

Blueshift Asset Management’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$166K	Buy	+15,371	New	+$139K	0.04%	522

Other funds holding ORIC

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Blueshift Asset Management's ORIC Position: Q2 2026 in Review

Blueshift Asset Management opened a new position in Oric Pharmaceuticals (ORIC) in Q2 2026: 15,371 shares worth $166K. The stake represents 0.04% of the portfolio and ranks #522 among its holdings.

180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

Blueshift Asset Management held 15,371 shares of Oric Pharmaceuticals worth $166K as of Q2 2026.
Oric Pharmaceuticals was a new Blueshift Asset Management position in Q2 2026.
Oric Pharmaceuticals made up 0.04% of Blueshift Asset Management's portfolio in Q2 2026, its #522 holding.
180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Blueshift Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.